238 related articles for article (PubMed ID: 15846066)
1. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
DeLong P; Carroll RG; Henry AC; Tanaka T; Ahmad S; Leibowitz MS; Sterman DH; June CH; Albelda SM; Vonderheide RH
Cancer Biol Ther; 2005 Mar; 4(3):342-6. PubMed ID: 15846066
[TBL] [Abstract][Full Text] [Related]
2. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T cells in malignant pleural effusions subsequent to lung carcinoma and their impact on the course of the disease.
Budna J; Spychalski Ł; Kaczmarek M; Frydrychowicz M; Goździk-Spychalska J; Batura-Gabryel H; Sikora J
Immunobiology; 2017 Mar; 222(3):499-505. PubMed ID: 27773662
[TBL] [Abstract][Full Text] [Related]
4. Defect in recruiting effector memory CD8+ T-cells in malignant pleural effusions compared to normal pleural fluid.
Scherpereel A; Grigoriu BD; Noppen M; Gey T; Chahine B; Baldacci S; Trauet J; Copin MC; Dessaint JP; Porte H; Labalette M
BMC Cancer; 2013 Jul; 13():324. PubMed ID: 23816056
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions.
Budna J; Kaczmarek M; Kolecka-Bednarczyk A; Spychalski Ł; Zawierucha P; Goździk-Spychalska J; Nowicki M; Batura-Gabryel H; Sikora J
J Immunol Res; 2018; 2018():9876014. PubMed ID: 29785404
[TBL] [Abstract][Full Text] [Related]
6. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
Lievense LA; Bezemer K; Cornelissen R; Kaijen-Lambers ME; Hegmans JP; Aerts JG
Lung Cancer; 2017 May; 107():36-40. PubMed ID: 27168021
[TBL] [Abstract][Full Text] [Related]
7. CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion.
Chen YQ; Shi HZ; Qin XJ; Mo WN; Liang XD; Huang ZX; Yang HB; Wu C
Am J Respir Crit Care Med; 2005 Dec; 172(11):1434-9. PubMed ID: 16151041
[TBL] [Abstract][Full Text] [Related]
8. Foxp3 expressing CD4+ CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma.
Meloni F; Morosini M; Solari N; Passadore I; Nascimbene C; Novo M; Ferrari M; Cosentino M; Marino F; Pozzi E; Fietta AM
Hum Immunol; 2006; 67(1-2):1-12. PubMed ID: 16698419
[TBL] [Abstract][Full Text] [Related]
9. Predominance of Th17 over regulatory T-cells in pleural effusions of patients with lung cancer implicates a proinflammatory profile.
Prado-Garcia H; Romero-Garcia S; Rumbo-Nava U; Lopez-Gonzalez JS
Anticancer Res; 2015 Mar; 35(3):1529-35. PubMed ID: 25750307
[TBL] [Abstract][Full Text] [Related]
10. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer.
Maeda J; Ueki N; Ohkawa T; Iwahashi N; Nakano T; Hada T; Higashino K
Clin Exp Immunol; 1994 Nov; 98(2):319-22. PubMed ID: 7955539
[TBL] [Abstract][Full Text] [Related]
12. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
13. Correlation between DNA content, expression of Ki-67 antigen of tumor cells and immunophenotype of lymphocytes from malignant pleural effusions.
Sikora J; Dworacki G; Trybus M; Batura-Gabryel H; Zeromski J
Tumour Biol; 1998; 19(3):196-204. PubMed ID: 9591046
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC.
Li L; Chao QG; Ping LZ; Xue C; Xia ZY; Qian D; Shi-ang H
Cancer Biother Radiopharm; 2009 Jun; 24(3):357-67. PubMed ID: 19538059
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.
Zebrowski BK; Yano S; Liu W; Shaheen RM; Hicklin DJ; Putnam JB; Ellis LM
Clin Cancer Res; 1999 Nov; 5(11):3364-8. PubMed ID: 10589746
[TBL] [Abstract][Full Text] [Related]
16. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
17. Crucial role of CD4+CD 25+ FOXP3+ T regulatory cell, interferon-γ and interleukin-16 in malignant and tuberculous pleural effusions.
Ibrahim L; Salah M; Abd El Rahman A; Zeidan A; Ragb M
Immunol Invest; 2013; 42(2):122-36. PubMed ID: 23252864
[TBL] [Abstract][Full Text] [Related]
18. Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors.
Lee PH; Yang TY; Chen KC; Huang YH; Tseng JS; Hsu KH; Wu YC; Liu KJ; Chang GC
Sci Rep; 2021 Apr; 11(1):9381. PubMed ID: 33931705
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
Sterman DH; Recio A; Carroll RG; Gillespie CT; Haas A; Vachani A; Kapoor V; Sun J; Hodinka R; Brown JL; Corbley MJ; Parr M; Ho M; Pastan I; Machuzak M; Benedict W; Zhang XQ; Lord EM; Litzky LA; Heitjan DF; June CH; Kaiser LR; Vonderheide RH; Albelda SM; Kanther M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4456-66. PubMed ID: 17671130
[TBL] [Abstract][Full Text] [Related]
20. Elevated Circulating CD4
Hu X; Gu Y; Zhao S; Hua S; Jiang Y
Cancer Biother Radiopharm; 2019 Jun; 34(5):325-333. PubMed ID: 30925076
[No Abstract] [Full Text] [Related]
[Next] [New Search]
